EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) for Patients With Inborn Errors of Immunity From the Primary Immune Deficiency Treatment Consortium (PIDTC)

Danielle E Arnold, Hesham Eissa, Elizabeth Dunn, Geoffrey D E Cuvelier, Nicola A M Wright, Rebecca A Marsh, Suhag Parikh, Blachy Davila Saldana, Mark T Vander Lugt, Rosa Bacchetta, Lisa Forbes Satter, Shanmuganathan Chandrakasan und 17 weitere

The Journal of Allergy and Clinical Immunology: In Practice · 2026-08 · 14 (8) · 1893-1900

DOI: 10.1016/j.jaip.2026.05.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026-08. Verfasst von Danielle E Arnold und 28 weiteren Autor:innen. Beteiligte Einrichtung: Immune Deficiency Cellular Therapy, National Cancer Institute, Bethesda, Md. Hauptthemen laut MEDLINE: Immunologic Deficiency Syndromes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Evaluating natural history and outcomes of rare inborn errors of immunity (IEIs) has been challenging due to the diverse disease manifestations and lack of standardized data. OBJECTIVE: To develop a set of standardized, quantitative, generalizable data collection modules to measure organ dysfunction in IEIs, modeled on the previously validated Common Terminology Criteria for Adverse Event system for grading treatment toxicity. METHODS: Disease conditions were organized by organ system. Experts from the Primary Immune Deficiency Treatment Consortium identified essential features of severe combined immunodeficiency, chronic granulomatous disease, Wiskott-Aldrich syndrome, and primary immune regulatory disorders and compared these to Common Terminology Criteria for Adverse Event conditions, adding and refining features as needed. Dates of onset and resolution, disease-specific laboratory values, and therapeutic interventions were also incorporated. Modules were reviewed by protocol teams, key stakeholders, clinical coordinators, and statisticians to improve feasibility and completeness. RESULTS: We developed a tool called IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) containing 15 modules assessing 196 disease conditions. A grading system from 1 to 5 (mild, moderate, severe, life-threatening, fatal) permits longitudinal tracking of disease condition severity. Outcomes of interventions can be measured quantitatively by comparing scores before and after treatment. CONCLUSIONS: Standardized, quantitative assessment tools for IEIs can yield uniform data sets to illuminate their natural history and evaluate outcomes of interventions, not only to understand specific diseases but also to compare effects between disease entities. Tools, such as IMPACT, are essential for therapeutic trials for rare, complex multisystem diseases such as IEIs and other disorders with protean manifestations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunologic Deficiency SyndromesHumansPhenotypeMonitoring, Immunologic

Stichwörter der Autor:innen

CTCAECase report formIMPACTInborn errors of immunityInflammatory diseaseLate effectsNatural historyPrimary immune regulatory disorderStandardized assessment

Autor:innen und Institutionen

  • Immune Deficiency Cellular Therapy, National Cancer Institute, Bethesda, Md.
  • Children's Hospital of Colorado, Department of Pediatrics, Blood and Marrow Transplant and Cellular Therapeutics, University of Colorado, Aurora, Colo.
  • Pediatric Allergy, Immunology, and Blood and Marrow Transplantation Division, University of California San Francisco, San Francisco, Calif.
  • Pediatric Oncology and Transplantation, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
  • Section of Hematology/Immunology, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
  • Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NINDS NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Arnold, D. E., Eissa, H., Dunn, E., Cuvelier, G. D. E., Wright, N. A. M., Marsh, R. A., Parikh, S., Saldana, B. D., Vander Lugt, M. T., Bacchetta, R., Satter, L. F., Chandrakasan, S., Kellner, E., Allenspach, E. J., Schmitt, E. G., Logan, B., Burroughs, L., Cowan, M. J., Griffith, L. M., …, & Chan, A. Y. (2026). IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) for Patients With Inborn Errors of Immunity From the Primary Immune Deficiency Treatment Consortium (PIDTC). The Journal of Allergy and Clinical Immunology: In Practice, 14(8), 1893-1900. https://doi.org/10.1016/j.jaip.2026.05.025

Vancouver

Arnold DE, Eissa H, Dunn E, Cuvelier GDE, Wright NAM, Marsh RA, et al. IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) for Patients With Inborn Errors of Immunity From the Primary Immune Deficiency Treatment Consortium (PIDTC). The Journal of Allergy and Clinical Immunology: In Practice. 2026;14(8):1893-1900. doi:10.1016/j.jaip.2026.05.025

BibTeX
@article{Arnold2026,
  author = {Arnold, Danielle E and Eissa, Hesham and Dunn, Elizabeth and Cuvelier, Geoffrey D E and Wright, Nicola A M and Marsh, Rebecca A and Parikh, Suhag and Saldana, Blachy Davila and Vander Lugt, Mark T and Bacchetta, Rosa and Satter, Lisa Forbes and Chandrakasan, Shanmuganathan and Kellner, Erinn and Allenspach, Eric J and Schmitt, Erica G and Logan, Brent and Burroughs, Lauri and Cowan, Morton J and Griffith, Linda M and Notarangelo, Luigi and Pai, Sung-Yun and Pulsipher, Michael A and Dvorak, Christopher C and Haddad, Elie and Puck, Jennifer M and Torgerson, Troy R and Leiding, Jennifer W and Heimall, Jennifer and Chan, Alice Y},
  title = {IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) for Patients With Inborn Errors of Immunity From the Primary Immune Deficiency Treatment Consortium (PIDTC)},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2026},
  volume = {14},
  number = {8},
  pages = {1893--1900},
  doi = {10.1016/j.jaip.2026.05.025}
}
Kostenlos starten →